Real-Life Testing of the Prescription Opioid Misuse Index in French Primary Care

Catherine Laporte (), Frédéric Fortin, Julie Dupouy, Aurélie Quirin, Bruno Pereira, Chouki Chenaf, Jessica Delorme, Christine Maynié-François, Cédric Rat, Jordan Birebent, Jacques Rambaud, Christian Duale, Nicolas Kerckhove, Noémie Delage and Nicolas Authier
Additional contact information
Catherine Laporte: Clermont Auvergne Institut Pascal (INP), CNRS, Centre Hospitalo-Universitaire (CHU) Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Frédéric Fortin: Clermont Auvergne Institut Pascal (INP), CNRS, Centre Hospitalo-Universitaire (CHU) Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Julie Dupouy: Unite Mixte de Recherche (UMR) 1295 Inserm, Université Toulouse III, F-31000 Toulouse, France
Aurélie Quirin: Clermont Auvergne Institut Pascal (INP), CNRS, Centre Hospitalo-Universitaire (CHU) Clermont-Ferrand, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Bruno Pereira: Unité de Biostatistiques, Direction de la Recherche Clinique et de l’Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France
Chouki Chenaf: CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Jessica Delorme: CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Christine Maynié-François: UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive (LBBE), Équipe Evaluation et Modélisation des Effets Thérapeutiques (EMET), Université Claude Bernard Lyon 1, F-69100 Lyon, France
Cédric Rat: Département de Médecine Générale, Université de Nantes-INSERM U1302/CNRS EMR6001-Équipe 2, F-44035 Nantes, France
Jordan Birebent: Unite Mixte de Recherche (UMR) 1295 Inserm, Université Toulouse III, F-31000 Toulouse, France
Jacques Rambaud: Département de Médecine Générale, Université Montpellier, F-34090 Montpellier, France
Christian Duale: Unité de Biostatistiques, Direction de la Recherche Clinique et de l’Innovation, CHU Clermont-Ferrand, F-63000 Clermont-Ferrand, France
Nicolas Kerckhove: CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Noémie Delage: CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France
Nicolas Authier: CHU Clermont-Ferrand, Service de Pharmacologie Médicale, Centre d’Addictovigilance et Pharmacovigilance, Centre Evaluation et Traitement de la Douleur, Inserm, Neuro-Dol, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France

IJERPH, 2022, vol. 19, issue 22, 1-13

Abstract: Analgesic opioid (AO) misuse by patients ranges from 0% to 50%. General practitioners are the first prescribers of AO. Our objective was to validate the Prescription Opioid Misuse Index (POMI) in primary care. We conducted a psychometric study in patients with chronic pain who had been taking AOs for at least 3 months and were followed in general practice. Patients responded to the POMI at inclusion and after 2 weeks. The reference used was the DSM-V. Sixty-nine GPs included 160 patients (87 women, 54.4%), mean age 56.4 ± 15.2 years. The total POMI score was 1.50 ± 1.27, and 73/160 (45.6.0%) had a score ? 2 (misuse threshold). Internal validity was measured with the Kuder–Richardson coefficient, which was 0.44. Correlations between each item and the total score ranged from 0.06 to 0.35. Test–retest reliability was determined from 145 patients: Lin’s concordance coefficient was 0.57 [0.46, 0.68]. Correlation with the DSM-V (Spearman’s coefficient) was 0.52. The POMI does not have sufficient psychometric properties to be recommended as a tool to identify the misuse of AOs in primary care. This study clearly showed that there is a need to create a monitoring tool specific to primary care.

Keywords: primary care; general medicine; pain; analgesics; misuse; screening (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/22/14845/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/22/14845/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:22:p:14845-:d:969828

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().